New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DRYS;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 24, 2014
09:18 EDTDRYSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Microsoft (MSFT), up 4.3%... KLA-Tencor (KLAC), up 8.8%... Rubicon Project (RUBI), up 17.8%... Gigamon (GIMO), up 16%. ALSO HIGHER: Procter & Gamble (PG), up 2.7% after earning report, announcing plans to exit Duracell business by creating a stand-alone Duracell company... Vitae Pharmaceuticals (VTAE), up 40% following its report of top-line results from two Phase 1 clinical trials... Digital River (DRIV), up 47% after agreeing to be acquired by investor group for $26.00 per share. LOWER: Amazon (AMZN), down 9.3%, downgraded at Cowen and Janney Capital following the company's Q3 report... DryShips (DRYS), down 26% after filing an automatic common stock shelf... NPS Pharmaceuticals (NPSP), down 4.4% following PDUFA date for Natpara extended three months to January 24... Abercrombie & Fitch (ANF), down 4% after downgraded at Goldman and BMO Capital. DOWN AFTER EARNINGS: Pandora (P), down 7%... Synaptics (SYNA), down 9.9%... Flowserve (FLS), down 5%... New Oriental Education (EDU), down 4%.
08:51 EDTDRYSDryShips 250M shares Secondary priced at $1.40
DryShips announced that it priced the offering of 250M sharse of its common stock at a price of $1.40 per share. As part of the offering, George Economou, the Company's Chairman, President and Chief Executive Officer, has purchased $80 million, or 57,142,857 shares, of common stock in the offering at the public offering price. RS Platou Markets, Inc. and Pareto Securities Inc. are acting as joint lead managers, joint bookrunners and placement agents in the offering.
08:15 EDTJNJJohnson & Johnson management to meet with JPMorgan
Meetings to be held in Chicago/Kansas City on October 29 hosted by JPMorgan.
06:32 EDTJNJJohnson & Johnson found 'not liable' in all-metal hip implant suit, WSJ reports
Subscribe for More Information
October 23, 2014
18:52 EDTDRYSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Rubicon Project (RUBI), up 19.2%... KLA-Tencor (KLAC), up 15.8%... Gigamon (GIMO), up 13.5%... Maxwell (MXWL), up 11.3%... Qlik Technologies (QLIK), up 9.8%... NetSuite (N), up 5.5%... Microsoft (MSFT), up 3.3%... Juniper Networks (JNPR), reverses in after-hours trading and is up 1.4% after reporting third quarter results and announcing a $1.1B increase to the company's share repurchase authorization. ALSO HIGHER: Vitae Pharmaceuticals (VTAE), up 38.6% following positive top-line results from two Phase 1 clinical trials of BI1181181/VTP-37948... Pfizer (PFE), up 1.8% after announcing a new $11B share repurchase program. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.7%... Synaptics(SYNA), down 12.7%... Pandora (P), down 6.8%... Lattice Semiconductor (LSCC), down 5.6%... Maxim Integrated (MXIM), down 5.8%. ALSO LOWER: DryShips (DRYS), down 16.5% after filing an automatic common stock shelf... NPS Pharmaceuticals (NPSP), down 7.9% following PDUFA date for Natpara extended three months to January 24... GoPro (GPRO), down 2.8% after being initiated with an Underperform at Oppenheimer.
16:42 EDTDRYSDryShips files automatic common stock shelf
DryShips announced that it launched an offering of its common stock, par value $0.01 per share. RS Platou Markets, Inc. and Pareto Securities Inc. are acting as joint lead managers, joint bookrunners and placement agents in the offering. ABN AMRO Securities LLC is acting as joint lead manager and placement agent. DVB Capital Markets LLC is acting as co-manager and placement agent. RS Platou Markets AS and Pareto Securities AS are acting as placement agents. RS Platou Markets AS and Pareto Securities AS are not U.S. registered broker-dealers and to the extent that this offering is made within the United States, their activities will be effected only to the extent permitted by Rule 15a-6 of the Securities Exchange Act of 1934, as amended. The company intends to use the net proceeds from the offering to repurchase a portion of its $700M principal amount of indebtedness under the 5.0% Convertible Senior Notes maturing on December 1, 2014.
05:58 EDTJNJStocks with implied volatility below IV index mean; XLNX JNJ
Subscribe for More Information
October 22, 2014
17:50 EDTJNJBavarian Nordic announces expanded collaboration with Janssen on MVA-BN
Bavarian Nordic A/S announced that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to expand the collaboration announced earlier to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets. Bavarian Nordic and Janssen will collaborate on the evaluation of MVA-BN for three additional infectious disease targets. Janssen is granted the exclusive option to collaborate on one or more of the targets, following scientific evaluation of MVA-BN-based vaccine candidates, which will be developed by Bavarian Nordic.
05:31 EDTJNJJohnson & Johnson announces commitment to speed Ebola vaccine development
Subscribe for More Information
October 20, 2014
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
09:52 EDTDRYSDryShips unit awarded contract extensions
Subscribe for More Information
09:49 EDTDRYSDryShips expects Q3 EBITDA $265M-$300M
Subscribe for More Information
09:45 EDTDRYSOcean Rig UDW says stock price does not reflect true value
George Economou, Ocean Rig UDW CEO, said in a press release, "We do not believe that the current stock price of Ocean Rig reflects the true value of company, which stock price has be adversely affected by the recent volatility of the oil price. The loan from Ocean Rig to Dryships is just a backstop in case Dryships need more time to execute on its various alternatives to refinance its Convertible Notes due December 1, 2014, and will be repaid as soon as possible. Ocean Rig with its high specification, pure play UDW fleet and solid balance sheet and backlog is uniquely positioned amongst its clients. Ocean Rig's newbuilding program in 2016 and 2017 provides further growth into a market we believe in and its solid backlog supports for dividends and other value creation initiatives, such as the MLP." Ocean Rig shares are down 10c to $13.34 while its parent DryShips is rallying 24c to $1.93 in early trading.
09:39 EDTDRYSOcean Rig UDW lends $120M to DryShips, extends Petrobras contracts
Ocean Rig UDW (ORIG) said it has agreed to lend its parent company, DryShips (DRYS), up to $120M of immediate liquidity through a short-term unsecured loan. The proceeds will be used, if needed, to repay Dryshipsí 5% Convertible Notes maturing in Dec. 1. Ocean Rig has declared its third consecutive quarterly cash dividend with respect to the quarter ended September 30, of 19c per common share, to shareholders of record as of October 31, and payable on or about November 11. Ocean Rig added that it has been awarded extensions of the drilling contracts for its two ultra deepwater drillships, the Ocean Rig Corcovado and the Ocean Rig Mykonos by Petrobras (PBR) for drilling offshore Brazil. The contract extensions are subject to partner approvals. The term of each extension is for 1,095 days with a total combined revenue backlog of over $1.1Bm excluding reimbursement by Petrobras for contract related equipment upgrades. The new contracts will commence in direct continuation from the end of the current agreements with Petrobras, in Q1 and Q2 of 2015. Ocean Rig also signed an amendment with Total E&P Angola to extend the date by which Total E&P Angola should exercise the option to extend the term of the contract for two additional one-year periods. The first option is now exercisable until February 27, 2015 and the second option exercisable within one year after the date of exercise of the first option.
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use